Showing results (41-50 of 88) with videos related to

Sort By:
Pageof 9
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|October 31, 2020
Fear of cancer recurrence following allogeneic haematopoietic stem cell transplantation (HSCT) for haematological malignancy: A cross-sectional studyLisa Brice, Gemma McErlean, Caroline Donovan, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 16, 2016
Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaJohn M Burke, Richard H C van der Jagt, Brad S Kahl, et al.
Blood Advances|June 30, 2026
Validation of the newly introduced Deauville Score 5a in patients treated for advanced-stage classic Hodgkin LymphomaSimon Leiders, Dominic Ufton, Helen Kaul, et al.
Blood Advances|November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort dataLaurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
European Journal of Haematology|February 11, 2021
Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivorsHugo Vachon, Justyna Mierzynska, Mekdes Taye, et al.
The Australasian Journal of Dermatology|December 28, 2020
Mycosis fungoides and Sézary syndrome: Australian clinical practice statementFriyana K Bhabha, Christopher McCormack, Jillian Wells, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell LymphomaLaurie H Sehn, Alex F Herrera, Christopher R Flowers, et al.
Haematologica|October 14, 2011
Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemiaHarry Iland, Ken Bradstock, John Seymour, et al.
Leukemia & Lymphoma|October 6, 2022
Treatment pathways and clinical outcomes in Hodgkin lymphoma outside Europe and North America: results from the international, multicenter, retrospective, B-HOLISTIC studyBurhan Ferhanoglu, Tae Min Kim, Amado Karduss, et al.
The Lancet. Haematology|December 22, 2015
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based studyColm Keane, Frank Vari, Mark Hertzberg, et al.
Pageof 9